SCHEMBL5585841

SCHEMBL5585841

Fc1c[c]ccc1Oc1ccnc2cc(-c3ccc(OCCN4CCOCC4)cc3)sc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MST1R Q04912 2/20 0.45
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KDR P35968 5/20 0.40
FLT1 P17948 2/20 0.40
MET P08581 5/20 0.40
LTA4H P09960 2/20 0.40
ACHE P22303 3/20 0.39
BCHE P06276 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
AXL P30530 1/20 0.39
PRKAB2 O43741 1/20 0.38
LCK P06239 1/20 0.38
SRC P12931 1/20 0.38
EPHA2 P29317 1/20 0.38
FLT3 P36888 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563531 0.82 ACHE (0.47) NPC1RAB9AKDRFLT1MET
SCHEMBL13254390 0.80 LTA4H (0.44) MST1RNPC1RAB9AKDRFLT1
SCHEMBL5586102 0.79 MET (0.48) MST1RKDRFLT1METLTA4H
SCHEMBL3576981 0.79 AXL (0.52) MST1RKDRMETACHEAXL
SCHEMBL3569398 0.78 LTA4H (0.49) MST1RNPC1RAB9ALTA4HACHE
SCHEMBL10224017 0.77 AXL (0.56) MST1RKDRMETAXLFLT3
SCHEMBL3563044 0.76 MST1R (0.45) MST1RKDRMETLTA4HACHE
SCHEMBL308728 0.75 AXL (0.64) MST1RKDRFLT1METAXL
SCHEMBL896686 0.75 MET (0.64) MST1RKDRMETFLT3
SCHEMBL10224047 0.74 MCHR1 (0.45) MST1RKDRMETAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 MST1R 44/4885NPC1 1129/4885RAB9A 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.